<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16716">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02009709</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-0001</org_study_id>
    <nct_id>NCT02009709</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2</brief_title>
  <official_title>Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2 in Eyes With Keratoconus or Ectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Mack, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mack Eye Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the effectiveness and safety of corneal
      collagen cross-linking at irradiance levels of 9 and 18 mW/cm2.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Decrease in maximum corneal curvature</measure>
    <time_frame>3 and 6 months post-procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Keratoconus</condition>
  <condition>Corneal Ectasia</condition>
  <arm_group>
    <arm_group_label>9 mW/cm2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CCL-VARIO UV lamp Riboflavin 0.1% ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18 mW/cm2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CCL-VARIO at 18 mW/cm2 Riboflavin 0.1% ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin 0.1% ophthalmic solution</intervention_name>
    <description>Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.</description>
    <arm_group_label>9 mW/cm2</arm_group_label>
    <arm_group_label>18 mW/cm2</arm_group_label>
    <other_name>CXL</other_name>
    <other_name>CCL</other_name>
    <other_name>crosslinking</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CCL-VARIO UV lamp</intervention_name>
    <description>Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes</description>
    <arm_group_label>9 mW/cm2</arm_group_label>
    <other_name>CXL</other_name>
    <other_name>CCL</other_name>
    <other_name>crosslinking</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CCL-VARIO at 18 mW/cm2</intervention_name>
    <description>Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.</description>
    <arm_group_label>18 mW/cm2</arm_group_label>
    <other_name>CXL</other_name>
    <other_name>CCL</other_name>
    <other_name>crosslinking</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria

        Prospective subjects must meet all of the following criteria to be eligible for
        participation:

          -  18 years of age or older

          -  Signed written informed consent

          -  Willingness and ability to comply with schedule for follow-up visits

          -  Contact lens removal prior to evaluation and treatment

        Inclusion criteria for progressive keratoconus

        Prospective subjects must meet two of the following criteria:

          -  Having a diagnosis of progressive keratoconus:

          -  An increase of ≥ 1.00 D in the steepest keratometry value

          -  An increase of  ≥ 1.00 D in astigmatism manifest refraction

          -  A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D on subjective
             manifest refraction

          -  Presence of central or inferior steepening on the Pentacam map.

          -  Axial topography consistent with keratoconus

          -  Steepest keratometry (Kmax) value ≥ 47.00 D

        Inclusion criteria for ectasia

        Prospective subjects must meet the following criteria:

          -  History of having undergone a keratorefractive procedure

          -  Meeting two of the following criteria

          -  Steepening by topography, either Pentacam or Humphrey

          -  Thinning of cornea

          -  Shift in the position of thinnest portion of cornea

          -  Change in refraction with increasing myopia

          -  Development of myopic astigmatism

          -  Development of irregular astigmatism

          -  Loss of best spectacle corrected acuity. 6.2 Exclusion Criteria

        Subjects meeting any of the following criteria will be excluded from this protocol:

          -  Eyes classified as either normal, atypical normal,

          -  Corneal pachymetry ≤ 350 microns at the thinnest point measured by Pentacam in the
             eye to be treated

          -  A history of chemical injury or delayed epithelial healing in the eye to be treated.

          -  Pregnancy (including plan to become pregnant) or lactation during the course of the
             study

          -  A known sensitivity to study medications

          -  Patients with nystagmus or any other condition that would prevent a steady gaze
             during the treatment

          -  Inability to cooperate with diagnostic tests.

          -  Patients with a current condition that, in the investigator's opinion, would
             interfere with or prolong epithelial healing.

          -  Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking
             treatment.

          -  Patients who are unable to remain supine and tolerate a lid speculum for an
             extended period of time.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Mack, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mack Eye Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert J Mack, M.D.</last_name>
    <phone>847-755-9393</phone>
    <email>rjsmack@aol.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mack Eye Center</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Baruch</last_name>
      <phone>847-755-9393</phone>
      <email>adamb@occhicago.com</email>
    </contact>
    <investigator>
      <last_name>Robert J Mack, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Denny, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Puja Shah, OD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>December 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mack Eye Center</investigator_affiliation>
    <investigator_full_name>Robert Mack, M.D.</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>keratoconus</keyword>
  <keyword>collagen crosslinking</keyword>
  <keyword>crosslinking</keyword>
  <keyword>ectasia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dilatation, Pathologic</mesh_term>
    <mesh_term>Keratoconus</mesh_term>
    <mesh_term>Corneal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
